A Phase 1 Study of TJ011133 Administered Alone or in Combination with Pembrolizumab or Rituximab in Subjects with Relapsed/Refractory Advanced Solid Tumors and Lymphoma

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Solid Tumors
    Non-hodgkin Lymphoma, Unspecified
  • Age: Between 18 - 100 Years
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1) Histological or cytological diagnosis of solid tumor who have relapsed or progressed and who are ineligible for all therapies with demonstrated clinical benefit 2) Available fresh metastatic biopsy sample prior to study entry and one mandatory on-treatment tumor biopsy, unless there is difficulty obtaining the sample

You may not be eligible for this study if the following are true:

  • 1. Patients with known symptomatic central nervous system tumors or known central nervous system metastases or leptomeningeal disease requiring steroids. Patients who document stable and central nervous system metastases and are off steroids for more than 4 weeks may be enrolled in the study 2. Patients with Burkitt’s lymphoma, lymphoblastic lymphoma, Richter's transformation, primary effusion lymphoma or chronic lymphocytic leukemia/small lymphocytic lymphoma 3. Patients with mantle cell lymphoma


If you are registered as a volunteer, please login to the dashboard to send referrals.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.